Corporate Banner
Satellite Banner
Crystallography
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Evotec and Harvard University to Collaborate on Development of New Class of Antibacterials

Published: Thursday, May 16, 2013
Last Updated: Thursday, May 16, 2013
Bookmark and Share
Target PGB (peptidoglycan biosynthesis) is the focus of collaboration.

Evotec AG announced a research collaboration with Harvard University aimed at discovering and developing novel anti-bacterial agents based on a highly validated target family involved in bacterial cell wall biosynthesis.

Under the Agreement, researchers at Harvard and Evotec will collaboratively identify and optimize small molecule inhibitors of bacterial cell wall synthesis, based on enabling technologies and chemical starting points licensed from Harvard. Using its comprehensive drug discovery infrastructure and expertise in addressing anti-bacterial targets, Evotec will specifically target peptidoglycan biosynthesis (PGB). The approach leverages promising chemical starting points, biological and structure-guided techniques allied with extensive medicinal chemistry expertise. The commercialisation of the resulting assets will be through Evotec.

“We are pleased to have entered into this collaboration with Harvard in the antibacterial space”, said Dr Werner Lanthaler, CEO of Evotec. “The lack of new antibacterials has been broadly recognised as a major unmet medical need as antibiotics pipelines are drying up while resistance against existing drugs is on the rise. We are excited to team up with our colleagues at Harvard to systematically target a highly validated but under-exploited anti-bacterial target family.”

Dr Vivian Berlin, Director Business Development in Harvard’s Office of Technology Development, added: “Target PGB builds on  research at Harvard on bacterial cell wall biosynthesis, which is at the perfect stage of development to partner with Evotec. Our goal in collaborating with Evotec is to accelerate the research and advance the project toward the clinic. This collaboration benefits from our aligned vision, complementary skills and the strong relationship we have built with Evotec in our other ongoing collaborations.

Exploiting proprietary assays, chemical starting points, and x-ray crystallographic tools from Harvard, the collaboration paves the way to develop novel antibacterial agents targeting PGB. The collaboration leverages the longstanding research of Daniel Kahne and Suzanne Walker, Professors in the Department of Chemistry and Chemical Biology and in the Departments of Biological Chemistry and Molecular Pharmacology and Microbiology and Immunobiology, respectively, and Evotec’s experience in the antibacterial space.
 
“We are pleased to combine forces with Evotec to exploit our knowledge of bacterial cell wall and in particular peptidoglycan biosynthesis for antibacterial drug discovery” said Prof Daniel Kahne. “We are confident this collaboration will put us in a strong position to translate the science and develop a new class of antibiotics against this well conserved target.”


Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,400+ scientific posters on ePosters
  • More than 3,700+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Evotec Extends Medicinal Chemistry Collaboration with Ono Pharmaceutical
Ono to access Evotec’s ion channel drug discovery platform and expertise and Evotec to receive research funding and milestone payments.
Monday, October 19, 2009
EVOTEC Announces RESEARCH Agreement on Fragment-Based Drug Discovery with Cubist
Cubist will use Evotec’s fragment screening technology to complement discovery research efforts in two of its antibacterials programs.
Wednesday, July 15, 2009
Evotec Expands Collaboration With InterMune
InterMune, Inc., has signed a second drug discovery contract with Evotec.
Friday, March 07, 2008
Evotec Extends Ongoing Collaboration with CHDI Worth up to US$ 37 Million
Three-year extension for integrated drug discovery support in the search of novel drug candidates for the treatment of Huntington Disease.
Tuesday, February 19, 2008
Evotec to Acquire Renovis, Seek NASDAQ Listing
Evotec AG and Renovis, Inc. today announced that they have entered into a definitive agreement under which Evotec will acquire Renovis, a biopharmaceutical company focused on the discovery and development of drugs for major medical needs in the areas of pain and inflammatory diseases, in a stock-for-stock transaction valued at approximately US$ 151.8 million.
Monday, December 24, 2007
Evotec Completes Divesture of Chemical Development Business to Aptuit
Evotec AG today announced that it has completed the sale of its Chemical Development Business to Aptuit, Inc. for a total consideration of £ 31.5 million (approx. EUR 44 million) effective November 30, 2007.
Monday, December 24, 2007
Evotec to Launch its First Innovation Centre for Fragment Based Drug Discovery
Fragment based drug discovery offers an alternative approach for identifying small molecule hits for a number of biological targets.
Monday, May 21, 2007
Scientific News
Crystal Clear Images Uncover Secrets of Hormone Receptors
NIH researchers gain better understanding of how neuropeptide hormones trigger chemical reactions in cells.
TOPLESS Plants Provide Clues to Human Molecular Interactions
Scientists at Van Andel Research Institute have revealed an important molecular mechanism in plants that has significant similarities to certain signaling mechanisms in humans, which are closely linked to early embryonic development and to diseases such as cancer.
Advancing Cancer Drug Design with Image of Key Protein
Scientists have pioneered the use of a high-powered imaging technique to picture in exquisite detail one of the central proteins of life – a cellular recycling unit with a role in many diseases.
Mould Unlocks New Route to Biofuels
Scientists at The University of Manchester have made an important discovery that forms the basis for the development of new applications in biofuels and the sustainable manufacturing of chemicals.
'Invisible' Protein Structure Explains the Power of Enzymes
A research group at Umeå University in Sweden has managed to capture and describe a protein structure that, until now, has been impossible to study.
Unraveling the Elusive Structure of HIV Protein
Snapshots of HIV virus’ proteins may help design new ways to fight the disease.
Blueprinting Cell Membrane Proteins
Recent breakthrough will make the blueprinting process faster, easier and cheaper, and should have major implications in the field of drug discovery and development.
Bacteria Use Chemical Harpoons to Hold on Their Hosts
Researchers reveal how a common disease causing bacteria latches on to the body during an infection.
Solving Streptide from Structure to Biosynthesis
Researchers reveal new information about how bacteria communicate via the protein, streptide.
Near-Atomic Resolution of Protein Structure Holds Promise for Drug Discovery
A new study shows that it is possible to use an imaging technique called cryo-electron microscopy to view the architecture of a metabolic enzyme bound to a drug that blocks its activity.
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,400+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
3,700+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FREE!